CUEDC2 and ovarian serous carcinoma: While Wang et al. found that CUEDC2 contributed to cisplatin-based chemotherapy resistance by regulating p38 MAPK signaling and was a promising biomarker and therapeutic target of cisplatin resistance in ovarian serous carcinoma [62].